Pfizer Inc. (PFE) - Stock Analysis

Last updated: Sep 6, 2026

Research Idea

Research content for general circulation. Not individualized advice. Methodology & Disclosures

Pfizer delivered an earnings beat, raised its 2026 revenue outlook, and has supportive regulatory and pipeline progress. Shares gained 15.3% over 21 sessions and closed at a new period high on August 19.

Loading chart data...

Idea window: 8/19/2026 – 8/26/2026Sector: Healthcare

AI Analyst Overview

Last Price
$28.45
Market Cap
$162.15B
1D Return
-1.25%
YTD Return
+20.14%

Loading chart data...

Valuation Metrics

P/E
37.6
P/B
1.9
P/S
2.5
EV/EBITDA
17.9
Div Yield
6.05%

Fundamental Analysis

3.0

Key Financial Insights: • Earnings Deterioration • Cash Flow Decline • Dividend Pressure PFE's quarterly losses, sharply weaker cash flow, and undercovered dividend outweigh modest liquidity and debt improvements, signaling heightened execution and capital-allocation risk.

DividendRisk
Liquidity

Price Behavior

6.0

Key Price Behavior Insights: • Higher highs • Recent pullback • Key breakout Support Level: $27.95–$28.05 Resistance Level: $29.02 PFE remains bullish over the last month, but watch $28.00 support and $29.02 resistance for confirmation of continued momentum.

bullish
cautious

Sentiment & News

5.0

Key News Insights: • Earnings Recovery • Patent Cliff • Cost Savings Pfizer's improving earnings, cost cuts, and oncology growth prospects support near-term momentum, but patent expirations, leverage, and dividend uncertainty remain key long-term risks.

Pfizer
Pharma
AI

AI Summary

5.0
Neutral

Pfizer is a cash-flow turnaround—not simply a cheap high-yield recovery—where upside depends on Seagen oncology launches and cost cuts restoring free cash flow enough to cover its dividend, debt, and R&D before patent expirations intensify; maintain a cautious stance until cash conversion, not adjusted EPS, materially improves.

OncologyUpside
DividendRisk
CashFlow
AI summary updated today

Description

Pfizer Inc. is a global biopharmaceutical company that discovers, develops, manufactures, markets and distributes prescription medicines and vaccines across a wide range of therapeutic areas, including cardiovascular, oncology, immunology, infectious disease and rare disorders. Its portfolio covers biologics, small molecules, immunotherapies, vaccines and biosimilars, and the company also conducts contract manufacturing and supplies products to wholesalers, hospitals, clinics, pharmacies and government agencies. Founded in 1849, Pfizer is headquartered in New York and maintains strategic collaborations with several pharmaceutical and biotech companies worldwide.

Idea History

DateCloseTickerCompanySummaryStatusP/L
Aug 19Aug 26PFEPfizer Inc.
Pfizer delivered an earnings beat, raised its 2026 revenue outlook, and has supportive regulatory and pipeline progress. Shares gained 15.3% over 21 sessions and closed at a new period high on August 19.
Closed+0.2%
Research content for educational purposes only. Not investment advice. All decisions are your responsibility.